Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeted therapies: Molecular selection for 'smart' study design in lung cancer.

Literature DB >> 20981127

Targeted therapies: Molecular selection for 'smart' study design in lung cancer.

Amanda Psyrri, Barbara Burtness.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2010 PMID： 20981127 DOI： 10.1038/nrclinonc.2010.156

Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675

× No keyword cloud information.

8 in total

1. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials.

Authors: Massimo Di Maio; Nicola Lama; Alessandro Morabito; Egbert F Smit; Vassilis Georgoulias; Koji Takeda; Elisabeth Quoix; Dora Hatzidaki; Floris M Wachters; Vittorio Gebbia; Chun-Ming Tsai; Carlos Camps; Wolfgang Schuette; Paolo Chiodini; Maria Carmela Piccirillo; Francesco Perrone; Ciro Gallo; Cesare Gridelli
Journal: Eur J Cancer Date: 2010-01-04 Impact factor: 9.162

2. Erlotinib in previously treated non-small-cell lung cancer.

Authors: Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal: N Engl J Med Date: 2005-07-14 Impact factor: 91.245

3. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

Authors: Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Sumitra Thongprasert; Eng Huat Tan; Kristine Pemberton; Venice Archer; Kevin Carroll
Journal: Lancet Date: 2005 Oct 29-Nov 4 Impact factor: 79.321

4. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Authors: Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn
Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544

5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors: Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal: N Engl J Med Date: 2009-08-19 Impact factor: 91.245

6. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Authors: Roy S Herbst; Yan Sun; Wilfried E E Eberhardt; Paul Germonpré; Nagahiro Saijo; Caicun Zhou; Jie Wang; Longyun Li; Fairooz Kabbinavar; Yukito Ichinose; Shukui Qin; Li Zhang; Bonne Biesma; John V Heymach; Peter Langmuir; Sarah J Kennedy; Hiroomi Tada; Bruce E Johnson
Journal: Lancet Oncol Date: 2010-07 Impact factor: 41.316

7. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.

Authors: George N Naumov; Monique B Nilsson; Tina Cascone; Alexandra Briggs; Oddbjorn Straume; Lars A Akslen; Eugene Lifshits; Lauren Averett Byers; Li Xu; Hua-Kang Wu; Pasi Jänne; Susumu Kobayashi; Balazs Halmos; Daniel Tenen; Xi M Tang; Jeffrey Engelman; Beow Yeap; Judah Folkman; Bruce E Johnson; John V Heymach
Journal: Clin Cancer Res Date: 2009-05-15 Impact factor: 12.531

8. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.

Authors: John V Heymach; Bruce E Johnson; Diane Prager; Edit Csada; Jaromír Roubec; Milos Pesek; Irena Spásová; Chandra P Belani; István Bodrogi; Shirish Gadgeel; Sarah J Kennedy; Jeannie Hou; Roy S Herbst
Journal: J Clin Oncol Date: 2007-09-20 Impact factor: 44.544